Fig. 7

Twice daily dosing of GKT771 at onset of advanced HCC reduces HCC lesions. Mice received weekly DEN (35 mg/kg) injections for 25 or 20 weeks and received twice or single daily doses of vehicle/GKT771 via oral gavage in an early or delayed treatment regimen, respectively. a Mice were sacrificed and morphometric data (body, liver and spleen weight) was recorded. Data shown as mean ± SD. b Macroscopically visible tumors were counted and subdivided into three categories (large, intermediate, small). Data shown as mean ± SD. ^nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-treated healthy controls, unless indicated differently. c: mRNA expression of HCC markers (AFP and GP3) in tumors and non-tumoral surrounding liver tissue of vehicle (light grey bars) and GKT771 treated (dark grey bars) mice was determined via RT-qPCR. Data shown as mean ± SEM. ^nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-treated healthy controls, unless indicated differently